Advertisement

Kaleido Biosciences, Inc. KLDO

Set alert

Price alert · KLDO

All alert types
0.00 USD 0.00 0.00%

At close · Oct 29

0.0001 Day range 0.0001
0.00001 52-week range 0.005
YTD
0.00%
1 year
0.00%
Open
0.0001
Prev close
0.0001
Mkt cap
4.26K
Vol
1.05K
Avg vol
942
EPS
-2.16
P/E
0.00
Div yield
0.00%
More statistics
Low
0.0001
High
0.0001
Forward P/E
-0.06
Beta
-0.10
Short ratio
29.34
Inst. own
79.77%
Dividend
0.00
Ex-div date
Earnings
May 3, 2022
50-d avg
1.15
200-d avg
3.55
1y target
22.00

2Y chart

Chart tools
Interval

Signals (56)
NameDateAgo
MACD: Sell SignalSep 4, 20261 month ago
MACD: Buy SignalAug 4, 20262 months ago
MACD: Sell SignalJul 29, 20263 months ago
RSI: OversoldJul 29, 20263 months ago
MACD: Buy SignalJul 6, 20263 months ago
MACD: Sell SignalJun 9, 20264 months ago
SMA: BearishJun 4, 20264 months ago
SMA: BullishJun 2, 20265 months ago
MACD: Buy SignalJun 2, 20265 months ago
RSI: OverboughtJun 2, 20265 months ago
MACD: Sell SignalMay 4, 20266 months ago
SMA: BearishApr 29, 20266 months ago
SMA: BearishApr 29, 20266 months ago
SMA: BullishApr 28, 20266 months ago
RSI: OverboughtApr 28, 20266 months ago
MACD: Buy SignalJan 6, 20269 months ago
MACD: Sell SignalDec 10, 202510 months ago
SMA: BearishDec 5, 202511 months ago
SMA: BearishDec 5, 202511 months ago
SMA: BullishDec 4, 202511 months ago
SMA: BullishDec 4, 202511 months ago
RSI: OverboughtDec 4, 202511 months ago
MACD: Buy SignalNov 20, 202511 months ago
MACD: Sell SignalOct 30, 20251 year ago
SMA: BearishOct 27, 20251 year ago
SMA: BearishOct 27, 20251 year ago
SMA: BullishOct 23, 20251 year ago
SMA: BullishOct 23, 20251 year ago
RSI: OverboughtOct 23, 20251 year ago
MACD: Buy SignalOct 7, 20251 year ago
MACD: Sell SignalSep 24, 20251 year ago
SMA: BearishSep 23, 20251 year ago
SMA: BearishSep 23, 20251 year ago
SMA: BullishSep 22, 20251 year ago
SMA: BullishSep 22, 20251 year ago
MACD: Buy SignalSep 22, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
SMA: BearishAug 28, 20251 year ago
SMA: BearishAug 28, 20251 year ago
SMA: BullishAug 21, 20251 year ago
RSI: OverboughtAug 21, 20251 year ago
MACD: Buy SignalJun 3, 20251 year ago
SMA: BearishMay 7, 20251 year ago
MACD: Sell SignalMay 2, 20251 year ago
SMA: BullishMay 1, 20251 year ago
SMA: BearishApr 30, 20251 year ago
SMA: BullishApr 21, 20251 year ago
MACD: Buy SignalApr 21, 20251 year ago
RSI: OverboughtApr 21, 20251 year ago
SMA: BearishApr 15, 20251 year ago
SMA: BullishApr 14, 20251 year ago
MACD: Sell SignalApr 2, 20251 year ago
SMA: BearishApr 1, 20251 year ago
SMA: BullishMar 31, 20251 year ago
SMA: BearishMar 28, 20251 year ago
RSI: OverboughtMar 25, 20251 year ago

Key statistics

Market cap
2.13M
Enterprise value
-32.01M
Trailing P/E
0.00
Forward P/E
-0.06
PEG ratio
0.00
Price / sales
2.49
Price / book
0.07
EPS (TTM)
-2.24
Beta
-0.10
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
855.00K
Revenue growth
-78.40%
Free cash flow
-37.76M
Total cash
55.66M
Total debt
21.52M
Return on equity
-276.59%
Shares outstanding
42.62M
Short % of float
14.19%
50-day average
1.15
200-day average
3.55

Analyst view

Consensus: hold

Hold
Price target (mean) 22.00

Next earnings

May 3, 2022

Expected May 3, 2022. Consensus EPS estimate -0.51.

Earnings history

Financials — quick view

All financials
KLDO Revenue — quarterly 492.00K
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021
KLDO Net income — quarterly -20.27M
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021
KLDO EPS — quarterly -0.48
2018-Q1 20182018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 2021

Earnings

KLDO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 3, 2022Mar 1, 2022-0.51———
Apr 6, 2022Dec 1, 2021-0.56———
Nov 1, 2021Sep 1, 2021-0.55———
Aug 11, 2021Jun 1, 2021-0.59———
May 4, 2021Mar 1, 2021-0.64———
Mar 3, 2021Dec 1, 2020-0.41———

Upgrades / downgrades

KLDO analyst upgrades and downgrades
DateFirmActionFromTo
Apr 4, 2022Chardan CapitaldownBuyNeutral
Jan 31, 2022Chardan Capitalmain—Buy
Nov 12, 2021Chardan Capitalmain—Buy
Nov 3, 2021JMP Securitiesmain—Market Outperform
Oct 19, 2021Morgan StanleydownEqual-WeightUnderweight
Mar 8, 2021Morgan Stanleymain—Equal-Weight

About Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kaleido.com

News

Your note

Sign in to keep a note on KLDO — it syncs with the Stock Master app.

Insider holders

KLDO insider holders
InsiderRelationLatest transactionDateShares held
BONNEY MICHAEL WOfficer and DirectorConversion of Exercise of derivative securityMar 3, 20190
FLAGSHIP VENTURES FUND IV GENERAL PARTNER L L CBeneficial Owner of more than 10% of a Class of SecurityPurchaseFeb 7, 20210
FLAGSHIP VENTURES FUND V GENERAL PARTNER L.L.CBeneficial Owner of more than 10% of a Class of SecurityPurchaseMar 3, 20190
MELAS-KYRIAZI THEODirectorPurchaseJun 3, 202033,333
MENICHELLA DANIEL L.Chief Executive OfficerPurchaseFeb 7, 202120,000
QUINN ANTHONY GDirectorConversion of Exercise of derivative securityMar 3, 201931,603

Institution ownership

KLDO institution ownership
Holder% heldSharesValueReported
Flagship Pioneering Inc.45.93%19,575,71046.79MDec 30, 2021
FMR, LLC14.99%6,389,15215.27MDec 30, 2021
Harbourvest Partners, LLC4.30%1,833,8324.38MDec 30, 2021
Vanguard Group, Inc. (The)2.43%1,037,3872.48MDec 30, 2021
Blackrock Inc.2.17%923,8312.21MDec 30, 2021
Baillie Gifford and Company1.69%721,5121.72MDec 30, 2021

Fund ownership

KLDO fund ownership
Holder% heldSharesValueReported
Fidelity Growth Company Fund5.41%2,303,8793.43MFeb 27, 2022
Federated Hermes Kaufmann Fund1.39%591,1401.04MJan 30, 2022
Fidelity Growth Company K6 Fund1.36%579,169862.96KFeb 27, 2022
Vanguard Total Stock Market Index Fund1.23%524,1781.25MDec 30, 2021
Fidelity Series Growth Company Fund1.16%493,648735.53KFeb 27, 2022
iShares Russell 2000 ETF1.04%444,924783.07KJan 30, 2022
Advertisement